DEA Updates Who Can Sign for Ordering Schedule I and II Drugs
Published Date: 3/20/2026
Rule
Summary
If you order Schedule I or II drugs using DEA Form 222, this update clears up who can sign and manage the form—only registrants, their partners, or officers can do it. It also removes old rules about the old triplicate form, making things simpler and clearer. These fixes don’t change any big rules and take effect on March 20, 2026, so no extra costs or hassles ahead!
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
Who Can Sign DEA Form 222
If you order Schedule I or II controlled substances using DEA Form 222, only the registrant (if an individual), a partner (if a partnership), or an officer (if a corporation, corporate division, association, trust, or other entity) may execute or revoke a Power of Attorney and sign the DEA Form 222. The rule also clarifies that a person who merely signed the most recent DEA registration application may not execute or revoke POAs or sign DEA Form 222s. These clarifications take effect March 20, 2026.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08595 — Specific Listing for Hexahydrocannabinol, A Currently Controlled Schedule I Substance
The DEA is giving hexahydrocannabinol (HHC) its own official spot on the list of Schedule I drugs, making it clear that HHC is controlled separately from other similar substances. This change starts May 4, 2026, and affects anyone making, selling, or using HHC, which stays illegal under federal law. No new fees or costs are introduced, but the update helps law enforcement and businesses know exactly where HHC stands.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2026-05463 — Correcting Amendment Reinstating “Grandfather” Exceptions to Restrictions on Private Transfer Fee Covenants; Correction
The Federal Housing Finance Agency fixed a small mistake in a recent rule about private transfer fee covenants. They clarified that the rule reinstating 'grandfather' exceptions isn’t asking for public comments. This correction took effect on March 20, 2026, and mainly affects homeowners and property buyers dealing with these fees.
Next: 2026-05492 — Retirement Security Rule: Definition of an Investment Advice Fiduciary: Notice of Court Vacatur
The court has canceled the Department of Labor’s 2024 rule that changed who counts as a trusted investment advisor for retirement plans. Starting April 20, 2026, the old rules from 2020 will be back in charge, affecting financial advisors and retirement plan managers. This means advisors should review their practices to stay on the right side of the law and avoid costly mistakes.